NHF’s QMS is ISO – 9001:2015 Certified · Government of Jamaica

An agency of the Ministry of Health & Wellness

NEW DRUGS ADDED TO NHF DRUG LIST – 4 New Generics & 4 New Formulations

NEW DRUGS ADDED TO NHF DRUG LIST – 4 New Generics & 4 New Formulations

A new active ingredient Dutasteride for treating Benign Prostatic Hyperplasia was added to the National Health Fund Drug List under the label Avodart 0.5milligram capsules with a subsidy of $108.09 per capsule. This brings the total number of active ingredients offered by the NHF to 188.

Four new generic drugs have been also added to the NHF Drug List for the treatment of major depression, diabetes, high blood pressure and ischaemic heart disease. They are respectively Dalsan 20 milligram tablets with a NHF subsidy of $111.63 per tablet; Aten 100 milligram tablets with a NHF subsidy of $6.88 per tablet; Glimulin-2 tablets with a subsidy of $29.31 per tablet and Clopidogrel-LAS 75 milligram tablets with a subsidy of $47.49 per tablet.

A new generic controlled release formulation for the drug Sodium Valproate, used in the treatment of epilepsy was also added to the NHF Drug List under the label of Valparin Chrono. The drug is available in 300 milligram tablets and 500 milligram tablets with a subsidy of $12.67 and $21,12 per tablet respectively.
In addition, a new controlled release formulation for Tamsulosin for the treatment of Benign Prostatic Hyperplasia was also added under the label Flomax 0.4milligram CR tablets with a subsidy of $64.82 per tablet.

The additions of these drugs ensure that beneficiaries enrolled with the NHF are able to access a wider variety of drugs to treat their condition, thereby ensuring greater compliance and better outcomes.

An agency of the Ministry of Health & Wellness
NHF’s QMS is ISO – 9001:2015 Certified

National Health Fund The Towers,
6th Floor 25 Dominica Drive,
Kingston 5

(876) 906-1106 / (876) 906-4381

1-888-DIAL-NHF (342-5643)

[email protected]

National Health Fund © 2024. All Rights Reserved.